Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 19/20 | 0.46 |
| ▸ | CA1 | P00915 | 10/20 | 0.46 |
| ▸ | CA9 | Q16790 | 9/20 | 0.46 |
| ▸ | CA12 | O43570 | 8/20 | 0.46 |
| ▸ | CA5A | P35218 | 2/20 | 0.37 |
| ▸ | CA4 | P22748 | 2/20 | 0.37 |
| ▸ | CA7 | P43166 | 2/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25211478 | 0.79 | ALDH1A1 (0.33) | CA2CA1CA9CA12 | |
| SCHEMBL31560168 | 0.79 | PSMB8 (0.32) | CA2CA1CA9CA12 | |
| SCHEMBL15193253 | 0.79 | TSHR (0.33) | CA2CA1CA9CA12 | |
| SCHEMBL1348016 | 0.79 | CA2 (0.43) | CA2CA1CA9CA12CA4 | |
| SCHEMBL6326036 | 0.76 | PSIP1 (0.38) | CA2CA1CA9CA12 | |
| SCHEMBL19259882 | 0.75 | LOX (0.53) | — | |
| SCHEMBL19259785 | 0.73 | LOX (0.54) | — | |
| SCHEMBL19259827 | 0.72 | LOX (0.56) | CA2CA1CA9CA5ACA4 | |
| SCHEMBL19259779 | 0.72 | LOX (0.55) | — | |
| SCHEMBL5804960 | 0.72 | CA2 (0.53) | CA2CA1CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101516837-A | Sulfonamide derivatives | HOFFMANN LA ROCHE (CH) | 2009-08-26 | — | — | CN | claimed |
| US-8349844-B2 | Substituted pyrazolo [1,5-A] pyrimidines as metabotropic glutamate antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120041002-A1 | SUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINES AS METABOTROPIC GLUTAMATE ANTAGONISTS | GATTI MCARTHUR SILVIA (CH) | 2012-02-16 | — | — | US | disclosed |
| US-8093263-B2 | Substituted pyrazolo [1,5-a] pyrimidines as metabotropic glutamate antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| CN-101273040-B | Diazolylpyrazolopyrimidines as MGLUR2 antagonists | HOFFMANN LA ROCHE | 2011-11-09 | — | — | CN | disclosed |
| US-7964633-B2 | such as N,N'-[hexane-1,6-diylbis(iminocarbonyl)]bis(3-chlorobenzenesulfonamide), used as Fructose-1,6-bisphosphatase inhibitors; metabolic disorders such as diabetes | HOFFMANN-LA ROCHE INC. (US) | 2011-06-21 | — | — | US | disclosed |
| EP-2081889-B1 | SULFONAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | disclosed |
| CN-1863789-B | Substituted isoquinolinones | PORTOLA PHARM INC | 2010-06-09 | — | — | CN | disclosed |
| EP-1934214-B1 | OXADIAZOLYL PYRAZOLO-PYRIMIDINES AS MGLUR2 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-04-07 | — | — | EP | disclosed |
| CN-101516837-A | Sulfonamide derivatives | HOFFMANN LA ROCHE (CH) | 2009-08-26 | — | — | CN | disclosed |
| CN-1863789-A | Substituted isoquinolinones | PORTOLA PHARM INC (US) | 2006-11-15 | — | — | CN | disclosed |
| US-20060223871-A1 | Thiophene-and thiazolesulfonamides as antineoplastic agents | GROSSMAN CORA S | 2006-10-05 | — | — | US | disclosed |
| EP-1442030-B1 | THIOPENE- AMD THIAZOLESULFONAMIDES AS ANTINEOPLASTIC AGENTS | LILLY CO ELI (US) | 2006-08-30 | — | — | EP | disclosed |
| US-7084170-B2 | Thiophene-amd thiazolesulfonamides as antineoplastic agents | ELI LILLY AND COMPANY (US) | 2006-08-01 | — | — | US | disclosed |
| EP-1667989-A1 | SUBSTITUTED ISOQUINOLINONES | Portola Pharmaceuticals, Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050113399-A1 | Substituted isoquinolinones | PORTOLA PHARMACEUTICALS, INC. (US) | 2005-05-26 | — | — | US | disclosed |
| WO-2005035520-A1 | SUBSTITUTED ISOQUINOLINONES | PORTOLA PHARMACEUTICALS, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20040198784-A1 | Thiophene-amd thiazolesulfonamides as antineoplastic agents | GROSSMAN CORA SUE (US) | 2004-10-07 | — | — | US | disclosed |
| EP-1442030-A1 | THIOPENE- AMD THIAZOLESULFONAMIDES AS ANTINEOPLASTIC AGENTS | ELI LILLY AND COMPANY (US) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003035629-A1 | THIOPENE- AMD THIAZOLESULFONAMIDES AS ANTINEOPLASTIC AGENTS | ELI LILLY AND COMPANY (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113399-A1 | Substituted isoquinolinones | PFKP, MPL, TBXA2R | CA2 4801/4885CA1 4876/4885CA9 4877/4885 |
| US-20120041002-A1 | SUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINES AS METABOTROPIC GLUTAMATE ANTAGONISTS | GRM1, GRM2, GRM3 | CA2 2665/4885CA1 2482/4885CA9 4684/4885 |
| US-20060223871-A1 | Thiophene-and thiazolesulfonamides as antineoplastic agents | TPMT, TST, MGMT | CA2 1394/4885CA1 1002/4885CA9 356/4885 |
| US-20040198784-A1 | Thiophene-amd thiazolesulfonamides as antineoplastic agents | ALDH1A2, MGMT, NR2E3 | CA2 2965/4885CA1 4169/4885CA9 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.